Fig. 3From: Individualised treatment targets in patients with type-2 diabetes and hypertensionHbA1c reduction by treatment target (Baseline, 6 and 12 months). a Patients with HbA1c target ≤6.5%. b Patients with HbA1c target > 6.5 to ≤7.0%. c Patients with HbA1c target > 7.0 to ≤7.5%. Data presented as median, 25th and 75th percentiles, maximum, and minimum valuesBack to article page